Drugs / CMV/AdV /EBV/BKV specific T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03594981 | Jan 2018 → Jul 2025 overdue | viral infectious disease | Catherine Bollard | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV/AdV /EBV/BKV specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03594981 ↗ |
| Modality | Cell therapy | “donor-derived cytotoxic T lymphocytes (CTLs)” NCT03594981 ↗ |
| Route | Intravenous | “slow intravenous injection” NCT03594981 ↗ |